As of April 19, 2017 ClinicalTrials.gov lists a phase 1 trial of PLB1003 which targets ALK. At this time the trial is at one site: Shanghai Chest Hospital.
To qualify you must have one measurable met in the body.
The trial identifier is: NCT03130881.